BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/12/2021 12:19:26 PM | Browse: 716 | Download: 1579
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 68661
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Clinical Trials Study
Article Title Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Manuscript Source Unsolicited Manuscript
All Author List Mao-Hui Yan, Fang Liu, Bao-Lin Qu, Bo-Ning Cai, Wei Yu and Xiang-Kun Dai
Funding Agency and Grant Number
Corresponding Author Fang Liu, MD, Associate Chief Physician, Department of Radiotherapy, The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China. liufangfsq@163.com
Key Words Esophageal squamous cell carcinoma; Esophagus cancer; Induction chemotherapy; Concurrent radiochemotherapy; Radiotherapy; Chemotherapy; Albumin-bound paclitaxel; Lobaplatin
Core Tip To investigate the efficacy and safety of induction chemotherapy with albumin-bound paclitaxel (ABP) plus lobaplatin followed by concurrent radiochemotherapy (RCT) for locally advanced esophageal cancer. A total of 29 patients were included, and 26 of them completed the treatment protocol. Induction chemotherapy with ABP plus lobaplatin followed by concurrent RCT is effective in patients with locally advanced esophageal squamous cell carcinoma, with mild adverse effects. Thus, this protocol is worthy of clinical promotion and application.
Publish Date 2021-11-12 11:22
Citation Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. World J Gastrointest Oncol 2021; 13(11): 1781-1790
URL https://www.wjgnet.com/1948-5204/full/v13/i11/1781.htm
DOI https://dx.doi.org/10.4251/wjgo.v13.i11.1781
Full Article (PDF) WJGO-13-1781.pdf
Full Article (Word) WJGO-13-1781.docx